Top

Published in:

01-01-2008 | Preclinical Study

Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells

Authors: Haiming Xu, Donghong Ju, Tiffany Jarois, Youming Xie

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Abstract

Clinical trials with proteasome inhibitor Bortezomib (also named Velcade or PS-341) has shown promising results for some cancers. However, other types of cancers including breast cancer do not respond well to Bortezomib. To understand the cause of the drug resistance, we compared the regulation of proteasome expression and the sensitivity to proteasome inhibitors between human breast cancer cells and nontumorigenic mammary epithelial cells. We found that, while the endogenous expression level is much higher, the potential of feedback expression in response to proteasome inhibitors is much lower in the breast cancer cells. Furthermore, the breast cancer cells are much more resistant to proteasome inhibitors compared to the nontumorigenic mammary epithelial cells. Biochemical analysis showed that the pathway of Bortezomib-induced apoptosis is apparently defective in the breast cancer cells. Together, these results provide an explanation for the inefficacy of Bortezomib in the clinical trials for breast cancer patients. The likelihood of combination therapy with Bortezomib and other anti-cancer agents for breast cancer is also discussed.

Hershko A, Ciechanover A, Varshavsky A (2000) The ubiquitin system. Nature Med 10:1073–1081CrossRef

Schwartz AL, Ciechanover A (1999) The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 50:57–74PubMedCrossRef

Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638–2645PubMed

Banerjee D, Liefshitz A (2001) Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res 21:3941–3947PubMed

Shah SA, Potter MW, McDade TP, et al (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110–122PubMedCrossRef

Goy A, Younes A, McLaughlin P, et al (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 23:667–675PubMedCrossRef

Pahler JC, Ruiz S, Niemer I, et al (2003) Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 9:4570–4577PubMed

Orlowski RZ, Voorhees PM, Garcia RA, et al (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058–3065PubMedCrossRef

Yang CH, Gonzalez-Angulo AM, Reuben JM, et al (2006). Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17:813–817PubMedCrossRef

10.

Markovic SN, Geyer SM, Dawkins F, et al (2005) A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103:2584–2589PubMedCrossRef

11.

Mackay H, Hedley D, Major P, et al (2005) A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11:5526–5533PubMedCrossRef

12.

Maki RG, Kraft AS, Scheu K, et al (2005) A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103:1431–1438PubMedCrossRef

13.

Shah MH, Young D, Kindler HL, et al (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10:6111–6118PubMedCrossRef

14.

Xie Y, Varshavsky A (2001) RPN4 is a ligand, substrate, and transcriptional regulator of the 26S proteasome: a negative feedback circuit. Proc Natl Acad Sci USA 98:3056–3061PubMedCrossRef

15.

Ju D, Wang L, Mao X, Xie Y (2004) Homeostatic regulation of the proteasome via an Rpn4-dependent feedback circuit. Biochem Biophys Res Commun 321:51–57PubMedCrossRef

16.

Fleming JA, Lightcap ES, Sadis S, Thoroddsen V, Bulawa CE, Blackman RK (2002) Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. Proc Natl Acad Sci USA 99:1461–1466PubMedCrossRef

17.

Meiners S, Heyken D, Weller A, et al (2003) Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem 278:21517–21525PubMedCrossRef

18.

Lee CS, Tee LY, Warmke T, et al (2004) A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem 91:996–1006PubMedCrossRef

19.

Lundgren J, Masson P, Realini CA, Young P (2003) Use of RNA interference and complementation to study the function of the Drosophila and human 26S proteasome subunit S13. Mol Cell Biol 23:5320–5330PubMedCrossRef

20.

Wójcik C, DeMartino GN (2002) RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Biol Chem 277:6188–6197PubMedCrossRef

21.

Ding Q, Dimayuga E, Markesbery WR, Keller JN (2006) Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J 20:1055–1063PubMedCrossRef

22.

Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR (1996) MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148:313–319PubMed

23.

Chen L, Madura K (2005) Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 65:5599–5606PubMedCrossRef

24.

Kumatori A, Tanaka K, Inamura N, et al (1990) Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 87:7071–7075PubMedCrossRef

25.

Cortes J, Thomas D, Koller C, et al (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10:3371–3376PubMedCrossRef

26.

Yu J, Tiwari S, Steiner P, Zhang L (2003) Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2:694–699PubMed

27.

Klostergaard J, Leroux ME, Auzenne E, et al (2006) Hyperthermia engages the intrinsic apoptotic pathway by enhancing upstream caspase activation to overcome apoptotic resistance in MCF-7 breast adenocarcinoma cells. J Cell Biochem 98: 356–369PubMedCrossRef

28.

Wallner KE, Banda M, Li GC (1987) Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Res 47:1308–1312PubMed

29.

Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL (1992) Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52:3648–3654PubMed

30.

Reedijk J (2003) New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA 100:3611–3616PubMedCrossRef

31.

Nawrocki ST, Carew JS, Pino MS, et al (2005) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658–11666PubMedCrossRef

32.

Fribley AM, Evenchik B, Zeng Q, et al (2006) Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 281:31440–31447PubMedCrossRef

33.

Zou W, Yue P, Lin N, et al (2006) Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12:273–280PubMedCrossRef

Title: Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells
Authors: Haiming Xu
Donghong Ju
Tiffany Jarois
Youming Xie
Publication date: 01-01-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9553-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases

Insulin-like growth factor binding proteins and breast cancer

Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer